Antibacterial drug developer Achaogen (NASDAQ: AKAO) has promoted Blake Wise to the position of president and chief operating officer, an expansion of his current role. Wise joined the South San Francisco-based company in 2015 as chief operating officer. Before joining Achaogen, Wise had held various posts at Genentech.
In other moves, Achaogen promoted Lee Swem to senior vice president and chief scientific officer, and Zeryn Sarpangal to senior vice president of corporate and people strategy. Achaogen also appointed Janet Dorling chief commercial officer. Dorling most recently served as vice president of global product strategy, breast cancer, for Roche’s Genentech unit.